AVITA Medical Reports Director/Officer Changes & Compensation
Ticker: AVHHL · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1762303
| Field | Detail |
|---|---|
| Company | Avita Medical, Inc. (AVHHL) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $702,000, $140,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, compensation
Related Tickers: AVM
TL;DR
AVITA Medical filed an 8-K detailing leadership changes and compensation updates.
AI Summary
AVITA Medical, Inc. filed an 8-K on October 17, 2025, reporting events as of October 16, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes Regulation FD Disclosures and Financial Statements and Exhibits.
Why It Matters
This filing indicates potential shifts in AVITA Medical's leadership and executive compensation structure, which could impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if related to compensation, can signal internal shifts that may affect company strategy and performance.
Key Players & Entities
- AVITA Medical, Inc. (company) — Registrant
- October 16, 2025 (date) — Date of earliest event reported
- October 17, 2025 (date) — Date of report
FAQ
Who are the directors or officers departing from AVITA Medical?
The filing indicates the departure of directors or certain officers, but specific names are not provided in the provided text.
Who has been elected as new directors for AVITA Medical?
The filing states the election of directors, but the names of the newly elected directors are not specified in the provided text.
Are there any new appointments for certain officers at AVITA Medical?
Yes, the filing mentions the appointment of certain officers, but their specific roles and names are not detailed in the provided text.
What is the nature of the compensatory arrangements being reported?
The filing covers compensatory arrangements of certain officers, but the specific details of these arrangements are not elaborated upon in the provided text.
What other items are included in this 8-K filing besides director and officer changes?
This 8-K filing also includes Regulation FD Disclosures and Financial Statements and Exhibits.
Filing Stats: 1,180 words · 5 min read · ~4 pages · Grade level 11.4 · Accepted 2025-10-16 19:37:29
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share RCEL The Nasdaq Stock Mar
- $702,000 — a base salary at an annualized rate of $702,000. In addition, he will be eligible for a
- $140,000 — anteed bonus payment for fiscal 2025 of $140,000. For fiscal year 2026 and subject to Mr
Filing Documents
- rcel-20251016.htm (8-K) — 54KB
- rcel-ex99_1.htm (EX-99.1) — 19KB
- img262816717_0.jpg (GRAPHIC) — 58KB
- 0001193125-25-241705.txt ( ) — 269KB
- rcel-20251016.xsd (EX-101.SCH) — 25KB
- rcel-20251016_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 16, 2025 , the Company issued a press release announcing the departure of Mr. Corbett and the appointment of Mr. Vance, as described in Item 5.02 above. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information set forth in Item 5.02 and Item 7.01, as well as Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release, dated October 16, 2025, issued by AVITA Medical, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVITA Medical, Inc. Date: October 16, 2025 By: /s/ David O'Toole David O'Toole Chief Financial Officer